Research
Hormonal
Obesity causes hypertension and chronic kidney disease through multiple mechanisms including increased renal tubular sodium reabsorption, sympathetic nervous system activation, RAAS activation, and physical compression of the kidneys by visceral fat.
Obesity is a direct cause of high blood pressure and kidney disease through specific physiological pathways like increased sodium retention and nerve system activation. Managing visceral fat is crucial for mitigating these risks.
GoodSupportsHIGH confidence
Obesity raises blood pressure by increasing renal tubular sodium reabsorption, impairing pressure natriuresis, and causing volume expansion via activation of the sympathetic nervous system and renin−angiotensin−aldosterone system and by physical compression of the kidneys, especially when there is increased visceral adiposity.
Why this rating
Supported by multiple clinical studies, animal models, and epidemiological data cited in the review.
Source
Obesity, hypertension, and chronic kidney disease
John E. Hall et al. · International Journal of Nephrology and Renovascular Disease · 2014
DOI 10.2147/ijnrd.s39739
narrative_reviewCited 516×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weight loss interventions, including caloric restriction and increased physical activity, are effective in lowering blood pressure and reducing proteinuria in obese individuals, though long-term maintenance may be difficult.Good
- RAAS blockade with ACE inhibitors or ARBs reduces proteinuria and slows the progression to end-stage renal disease in obese patients with proteinuria.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →